Yevgeniy Feyman is an adjunct fellow at the Manhattan Institute and a senior research assistant in the department of health policy and management at the Harvard T.H. Chan School of Public Health. He writes on health care policy, entitlement reform, and the Affordable Care Act. His past research has addressed a variety of issues including the cost of health care and entitlement reform, drug pricing reform, and hospital consolidation. His current work is focusing on the dynamics in the Medicare Advantage market and the role of patients-as-consumers in healthcare.


In 2013, Feyman, with colleagues Avik Roy and Paul Howard, released the Obamacare Impact Map, a state-by- state look at the effects of the Affordable Care Act. The map was cited numerous times on Capitol Hill; Republican strategist Karl Rove called the map an “indispensable tool” in understanding the law’s effects on Americans.


Feyman has written for various publications, including the Health Affairs Blog, Politico, National Affairs, Boston Globe’s STAT, the New York Times’ Room for Debate, and National Review Online. He has spoken on numerous radio and TV shows and is a contributor to The Apothecary, the Forbes health care blog on health care policy and entitlement reform. Feyman holds a B.A. in economics and political science from Hunter College of the City University of New York.


Recent Posts by Yevgeniy Feyman

The Burgeoning “Yelpification” Of Health Care: Foundations Help Consumers Hold A Scale And A Mirror To The Health Care System

Current information about health care quality is disconnected from what consumers want. Philanthropy has a role to play in bridging the disconnect.

May 25, 2017GrantWatch, Hospitals, Quality

National Health Spending: A Return To The ‘Old Normal?’

As we return to the “old normal” of health care cost growth, our health care system looks radically different under the hood. The close of this episode has important lessons for policymakers, the incoming Trump administration, and health policy analysts.

December 14, 2016Costs and Spending, Following the ACA

If A Drug Is Good Enough For Europeans, It’s Good Enough For Us

Note: This post is coauthored by Paul Howard and Yevgeniy Feyman of the Manhattan Institute. Meningitis is a terrible disease that can kill its victims in a single day. About 4,100 new cases are diagnosed annually in the U.S., with a mortality rate of more than 10 percent. Even with...

Payment Reform: Flat Facility Fees & ACOs Aren’t Enough

American hospitals are expensive. Reams of data show that hospital-based services are more expensive than the same services provided in other settings. Moreover, the cost of hospital services has grown faster than costs in other parts of our health care system; from 1997 to 2012, for instance,...